Persistence and drug tolerance in pathogenic yeast

Current Genetics

Volumn 63, Issue 1, 2017, Pages 19-22

  Bojsen, Rasmus ^a   Regenberg, Birgitte ^b   Folkesson, Anders ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antifungal; Pathogenic yeast; Persistence; Quiescence; Resistance; Tolerance; TOR

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL THERAPY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL WALL; DRUG TOLERANCE; GENOTYPE; GROWTH DISORDER; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRESS; SYSTEMIC MYCOSIS; WILD TYPE; YEAST; ADAPTATION; ANIMAL; ANTIFUNGAL RESISTANCE; CANDIDIASIS; DRUG EFFECTS; HOST PATHOGEN INTERACTION; HUMAN; MICROBIAL VIABILITY; MICROBIOLOGY; MYCOSES; PHENOTYPE; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ADAPTATION, BIOLOGICAL; ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; CELL CYCLE; DRUG RESISTANCE, FUNGAL; HOST-PATHOGEN INTERACTIONS; HUMANS; MICROBIAL VIABILITY; MYCOSES; PHENOTYPE; STRESS, PHYSIOLOGICAL; YEASTS;

EID: 84969822665     PISSN: 01728083     EISSN: 14320983     Source Type: Journal    
DOI: 10.1007/s00294-016-0613-3     Document Type: Review

References (37)

1. Allen C et al (2006) Isolation of quiescent and nonquiescent cells from yeast stationary-phase cultures. J Cell Biol 174:89–100. doi:10.1083/jcb.200604072
2. Allison KR, Brynildsen MP, Collins JJ (2011) Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473:216–220. doi:10.1038/Nature10069
3. Aragon AD et al (2008) Characterization of differentiated quiescent and nonquiescent cells in yeast stationary-phase cultures. Mol Biol Cell 19:1271–1280. doi:10.1091/mbc.E07-07-0666
4. Bojsen R, Regenberg B, Folkesson A (2014) Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phase. BMC Microbiol 14:305. doi:10.1186/s12866-014-0305-4
5. Bojsen R, Regenberg B, Gresham D, Folkesson A (2016) A common mechanism involving the TORC1 pathway can lead to amphotericin B-persistence in biofilm and planktonic Saccharomyces cerevisiae populations. Sci Rep 6:21874. doi:10.1038/srep21874
6. Brauer MJ et al (2008) Coordination of growth rate, cell cycle, stress response, and metabolic activity in yeast. Mol Biol Cell 19:352–367
7. De Virgilio C, Loewith R (2006) Cell growth control: little eukaryotes make big contributions. Oncogene 25:6392–6415. doi:10.1038/sj.onc.1209884
8. Dworkin J, Shah IM (2010) Exit from dormancy in microbial organisms. Nat Rev Microbiol 8:890–896. doi:10.1038/Nrmicro2453
9. Gray JV, Petsko GA, Johnston GC, Ringe D, Singer RA, Werner-Washburne M (2004) “Sleeping beauty”: quiescence in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 68:187–206. doi:10.1128/MMBR.68.2.187-206.2004
10. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, Burke MD (2012) Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A 109:2234–2239. doi:10.1073/pnas.1117280109
11. Grillot R, Lebeau B (2005) Systemic antifungal agents. In: Bryskier A (ed) Antimicrobial agents: antibacterials and antifungals. ASM Press, Washington DC, pp 1260–1287
12. Ho YH, Gasch AP (2015) Exploiting the yeast stress-activated signaling network to inform on stress biology and disease signaling. Curr Genet 61:503–511
13. Hof H (2008) Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Updat 11:25–31. doi:10.1016/j.drup.2008.01.001
14. Khot PD, Suci PA, Miller RL, Nelson RD, Tyler BJ (2006) A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1,6-glucan pathway genes. Antimicrob Agents Chemother 50:3708–3716. doi:10.1128/AAC.00997-06
15. Klosinska MM, Crutchfield CA, Bradley PH, Rabinowitz JD, Broach JR (2011) Yeast cells can access distinct quiescent states. Genes Dev 25:336–349. doi:10.1101/gad.2011311
16. LaFleur MD, Kumamoto CA, Lewis K (2006) Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 50:3839–3846. doi:10.1128/AAC.00684-06
17. Lafleur MD, Qi Q, Lewis K (2010) Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother 54:39–44. doi:10.1128/AAC.00860-09
18. Laporte D, Lebaudy A, Sahin A, Pinson B, Ceschin J, Daignan-Fornier B, Sagot I (2011) Metabolic status rather than cell cycle signals control quiescence entry and exit. J Cell Biol 192:949–957. doi:10.1083/jcb.201009028
19. Lempiainen H, Shore D (2009) Growth control and ribosome biogenesis. Curr Opin Cell Biol 21:855–863. doi:10.1016/j.ceb.2009.09.002
20. Levin BR, Rozen DE (2006) Non-inherited antibiotic resistance. Nat Rev Microbiol 4:556–562
21. Lewis K (2010) Persister cells. Annu Rev Microbiol 64:357–372. doi:10.1146/annurev.micro.112408.134306
22. Li P, Seneviratne CJ, Alpi E, Vizcaino JA, Jin LJ (2015) Delicate metabolic control and coordinated stress response critically determine antifungal tolerance of Candida albicans biofilm persisters. Antimicrob Agents Chemother 59:6101–6112. doi:10.1128/Aac.00543-15
23. Loewith R, Hall MN (2011) Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 189:1177–1201. doi:10.1534/genetics.111.133363
24. Low C-Y, Rotstein C (2011) Emerging fungal infections in immunocompromised patients F1000. Med Rep 3:14. doi:10.3410/m3-14
25. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554. doi:10.1056/NEJMoa022139
26. Martinez MJ et al (2004) Genomic analysis of stationary-phase and exit in Saccharomyces cerevisiae: gene expression and identification of novel essential genes. Mol Biol Cell 15:5295–5305. doi:10.1091/mbc.E03-11-0856
27. Mesa-Arango AC, Scorzoni L, Zaragoza O (2012) It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front Microbiol 3:286
28. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA (2003) Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 71:4333–4340
29. Mulcahy LR, Burns JL, Lory S, Lewis K (2010) Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192:6191–6199. doi:10.1128/JB.01651-09
30. Ortiz-Urquiza A, Keyhani NO (2015) Stress response signaling and virulence: insights from entomopathogenic fungi. Curr Genet 61:239–249
31. Pardee AB (1974) A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 71:1286–1290
32. Perlin DS (2011) Current perspectives on echinocandin class drugs. Future Microbiol 6:441–457. doi:10.2217/fmb.11.19
33. Regenberg B et al (2006) Growth-rate regulated genes have profound impact on interpretation of transcriptome profiling in Saccharomyces cerevisiae. Genome Biol 7:R107
34. Waldorf AR, Polak A (1983) Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother 23:79–85
35. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317. doi:10.1086/421946
36. Zaragoza D, Ghavidel A, Heitman J, Schultz MC (1998) Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway. Mol Cell Biol 18:4463–4470
37. Zilberberg MD, Shorr AF, Kollef MH (2008) Secular trends in candidemia-related hospitalization in the United States, 2000–2005. Infect Control Hosp Epidemiol 29:978–980. doi:10.1086/591033